@article{c8f945e607f544e1a2a94623771ea056,
title = "Clinical trial enrollment of adolescents and young adults with sarcoma",
abstract = "More than half of all sarcomas occur in adolescents and young adults (AYAs) aged 15 to 39 years. After the publication of the AYA series in the April 1, 2016 issue of Cancer, several leaders in the field of sarcoma across disciplines gathered to discuss the status of sarcoma clinical research in AYAs. They determined that a focused effort to include the underrepresented and understudied AYA population in current and future sarcoma clinical trials is overdue. Trial enrichment for AYA-aged sarcoma patients will produce more meaningful results that better represent the disease's biology, epidemiology, and treatment environment. To address the current deficit, this commentary outlines changes believed to be necessary to expediently achieve an increase in the enrollment of AYAs in sarcoma clinical trials. Cancer 2017;123:3434-40.",
keywords = "National Clinical Trials Network, adolescent, clinical trials, sarcoma, young adult",
author = "Davis, {Lara E.} and Janeway, {Katherine A.} and Weiss, {Aaron R.} and Chen, {Yen Lin E.} and Scharschmidt, {Thomas J.} and Mark Krailo and {Glade Bender}, {Julia L.} and Kopp, {Lisa M.} and Patel, {Shreyaskumar R.} and Schwartz, {Gary K.} and Horvath, {L. Elise} and Hawkins, {Douglas S.} and Chuk, {Meredith K.} and Reinke, {Denise K.} and Gorlick, {Richard G.} and Randall, {R. Lor}",
note = "Funding Information: Lara E. Davis reports grants from Novartis, personal fees from Eisai, and personal fees from Foundation Medicine outside the submitted work. Yen-Lin E. Chen reports grants and nonfinancial support (clinical trial support) from the Children{\textquoteright}s Oncology Group and NRG Oncology during the conduct of this study. Mark Krailo reports personal fees from Merck outside the submitted work. Shreyaskumar R. Patel reports grants and personal fees from Jans-sen, grants and personal fees from Eisai, grants from Morphotek, personal fees from EMD Serono, personal fees from CytRx, personal fees from Bayer, and personal fees from Eli Lilly outside the submitted work. R. Lor Randall reports working as a consultant for Zimmer Biomet. Funding Information: The Children{\textquoteright}s Oncology Group is supported by the National Clinical Trials Network through an operations center grant (U10CA180886) and a statistics and data center grant (U10CA180899). The Sarcoma Alliance for Research Through Collaboration is supported in part by the National Cancer Institute through a Specialized Program of Research Excellence grant (U54CA168512). Individual Sarcoma Alliance for Research Through Collaboration clinical trials have been supported by the QuadW Foundation, the Sarcoma Foundation of America, the US Department of Defense, Novartis, Aventis, Eli Lilly, Bristol-Myers Squibb, Hoffmann–La Roche, AstraZeneca, Synta, Tesaro, and Merck. Publisher Copyright: {\textcopyright} 2017 American Cancer Society",
year = "2017",
month = sep,
day = "15",
doi = "10.1002/cncr.30757",
language = "English (US)",
volume = "123",
pages = "3434--3440",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",
}